Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the only NOVOTECH news I found/heard at the webinair. Australia sites we will use for IPF are open and no specifics. The Pusan University is an active site for covid trials with priority recruitment. Really not as much info as I had hoped for. At least AGN is in the right places...GLTA...
/Downloads/Novotech_Client_Bulletin_South_Korea_1_June_2020%20(1).pdf
/Downloads/Novotech_Client_Bulletin_Australia_1_June_2020.pdf
NOVOTECH has set up the IPF / Chronic cough trials in Australia and new Zealand, NCT04318704 and S Korea research
Canada and the USFDA have given Clearance for proceeding with COVID Trials setups,NCT04382924.
AGN has raised enough money to proceed on both. Actual REAL actions with scientific data supporting the thesis's of treatment that four countries have accepted.
Yep still a speculative penny stock...GLTA...
Looks official now that this is posted on ClinicalTrials.gov. Says May 11 but this is the first I saw it...GLTA...
https://clinicaltrials.gov/ct2/show/NCT04382924?term=Ifenprodil&draw=2&rank=2
Well it looks like AGN Did/ Was/IS putting much more effort and now success with the multinational / USFDA Trial clearance approval. Apparently the South Korea Trials were / are still an 'ace in the whole' and progression is unclear. IMO. I hope there is some news by the time of the NOVOTECH webnair on Asia COVID efforts. 5 days?
Australia just updated their 'locations' May 27,
https://clinicaltrials.gov/ct2/show/NCT04318704?term=Ifenprodil&cond=idiopathic+fibrosis&draw=2&rank=1
Canada is on board and I would guess AGN has a pretty good idea of the sites there.
Now USFDA support and access to the hoards of patients here. I understand that Sites here in the USA have already been contacted per their Video. These could all be going very soon.
I dont see AGN being 'late', what with the tepid success of (Wuhan VI's)/Giliad's Remdesivir or Trump's Cloroquin (sp), etc. No silver bullets yet. Most scientists expect 'second waves' this fall.
I would also guess that just us watchers / holders have heard the news so far. I believe their pump is still to come. Success / successes with 'signals/data' will obviously be best / Huge. Yes still a speculative penny being flipped by many...GLTA...
BTW I support all poster's contributions and Rights to their Opinions...
They Did have much more effort and now success with the multinational / USFDA Trial approval and the SKorea Trials were / are still an 'ace in the whole'. IMO. I hope there is some news by the time of the NOVOTECH webnair on Asia COVID efforts. 6 days?
Australia just updated their 'locations' May 27,
https://clinicaltrials.gov/ct2/show/NCT04318704?term=Ifenprodil&cond=idiopathic+fibrosis&draw=2&rank=1
Canada is on board and I would guess AGN has a pretty good idea of the sites there.
Now USFDA support and access to the hoards of patients here. I understand that Sites here in the USA have already been contacted per their Video. These could all be going very soon.
I dont see AGN being 'late' with the tepid success of Wuhan VI's/Giliad's Remdesivir or Trump's Cloroquin (sp), etc, no silver bullets yet. Most scientists expect 'second waves' this fall.
I would also guess that just us watchers / holders have heard the news so far. I believe their pump is still to come. Success / successes with 'signals/data' will obviously be best / Huge. Yes still a speculative penny being flipped by many/most...GLTA...
BTW I support all poster's contributions...
They have that issue with H2Partners, about the 'hail damaged crops' coming up. It is a first case to court and may have some relevance. Now they'll spend more money on fighting who gets paid what % of$.02 and the order.
Stepping on their dicks and Our Money on so many actual things that this company should have been.
Look at Vadesa / Tony V spin off and where he is. Wish I would have sold with him, UCANN f*kt PRANA and Vadesa is Mega. He was right.
UCANN currently F*kn Shareholders, Partners and 'friends'...GLTA, somewhere else...
With the Proprietary extraction process, 911 patent, customers, harvests, current markets it's amazing what the actually results were...
http://www.ventura.courts.ca.gov/CivilCaseSearch/CaseReport/56-2018-00516131-CU-FR-VTA
I may have missed this but it may have been updated with sites in Australia and N Z. Either way nice to see progress...GLTA..
https://clinicaltrials.gov/ct2/show/NCT04318704?term=Ifenprodil&cond=idiopathic+fibrosis&draw=1&rank=1
S Korea is no push-over for research. We are lucky and must have promising affects with Ifenprodil to already receive Trial approval. Sure there is competition. I also notice that Degau (SE Korea near Pusan) was/is a hot spot for COVID so maybe there are sufficient patients in the needed conditions...GLTA...
"Major local pharmaceutical firms, including industry leader Celltrion Inc. here, and research organizations are in the process of conducting clinical trials on animals.
However, none of them yet have received approval for clinical trials on humans from the country's drug safety agency, the Ministry of Food and Drug Safety."
https://en.yna.co.kr/view/AEN20200603006100320?section=science/medicine
I still feel that the multinational Clinical Trials are the Gold standard...GLTA...
Great to hear that the multinational trials are close. A usual 30 days will probably be less and they seem to expect the USFDA to join Canada and Australia (others?) in allowing these Trials.
Also nice to hear contacts here in the US with proposed sites and obviously sufficient patients. US is #1 in COVID cases.
I also noticed Chris and Mark kept referring to SK Trials as a back-up/ace in the whole.
Seems they are placing much more effort and confidence in the multinational 2b/3 Trials' plans. I think this is the MUCH bigger News! ...GLTA...
Sorry to tell some here but AGN is a speculative stock. They are not Giliad with Remdesivir or Trump pumped Coloquin (sp?) with billions of $ for lawyers and truth bending advertisement.
AGN will need to have all the ducks in nice rows. S Korea appears to be silent which I expected. AGN is not a sponsor on this trial from what Dr Moreau said in the past. This is a Korean led investigational study, right?
Seems like it is vogue now to claim even mild results as great. The NDMA/ Sr1 antagonist angle is AGN's. Others have documented the science. I have bought my share and will await news from the several paths worldwide where experienced other scientists are taking seriously the possibilities of Ifenprodil presented by AGN and supporting Phase2/2b to 3 Clinical trials. Korea might be fully in process.
AGN has set up Trials for CC/IPF and now COVID and is producing the intravenous form of Ifenprodil along with having the 20mg pill form.
Not bad for a $2 bit bet, I'll let my money ride without genuflecting contortions to other's...GLTA...
BTW, 7 days to NOVOTECH Asia clinical trials update forum.
Folks are not healing well even after beating COVID. Long lung and other organ recovery times. I guess that is why we are here. It's the science of possible life saving help to beat COVID AND the recovery afterwards...GLTA...
https://www.medscape.com/viewarticle/931083
I saw this Novotech sponsored thingee. So maybe 10 days away for some info?...GLTA...
https://webinars.endpts.com/clinical-trial-continuity-in-asia-pacific-during-the-covid-19-pandemic/
NIH guidelines appear to want a full report at "completion" and then publication. CRIS implied confidentiality until publishing data thru International Committee of Medical Journal Editors. ?...GLTA... Discussing a "signal" is unclear to me. I guess AGN will have inside info as Trials proceed but making "claims" needs documented verification.?.
Lots of info and different procedures depending on ***.
https://www.ncbi.nlm.nih.gov/books/NBK286004/
Benefit patients and future research participants. An essential step in science is verification and replication of investigators' claims. Once investigators have published their findings, as responsible scientists they should allow other researchers to subject those findings to scrutiny. Allowing timely verification and reproduction serves the public good by preventing other researchers or clinicians from building on findings whose validity cannot be established and by preventing patients from receiving recommendations for clinical care that are based on invalid information. Moreover, sharing clinical trial data benefits patients by allowing other investigators to carry out additional analyses that provide valid scientific information about the effectiveness and safety of the study intervention. In addition, sharing clinical trial data prevents participants in future research from being placed at unwarranted risk because the benefits of an intervention are smaller or the risks greater than claimed in a publication. Furthermore, sharing clinical trial data may increase public trust in the scientific and clinical trials ecosystem.
Protect the professional interests of clinical trialists in gaining fair professional rewards for their intellectual effort and time by giving them reasonable time to analyze and publish data from a trial they have planned and carried out. In the long run, this protection of the interests of trialists will benefit the public and future patients by creating incentives for investigators to carry out clinical trials; conversely, failure to allow clinical trialists time to publish their findings will discourage investigators from proposing and conducting trials.
Protect the commercial interests of the sponsors in gaining regulatory approval for a product or indication they have developed and tested, so that they can gain fair financial rewards for their investment of financial and intellectual capital. If a sponsor shares extensive data before a product gains regulatory approval, follow-on developers may gain commercial and strategic advantages. In addition, as a matter of fairness, other companies should not use shared clinical trial data as the predominant basis for their own regulatory submissions—for example, seeking approval for a generic version of the product in a country that does not recognize data exclusivity. In the long run, such incentives to sponsors will benefit the public and future patients by incentivizing investors and companies to develop new medical products and bring basic science discoveries to patients; failure to do so will discourage investments in health care innovation and product development that would ultimately benefit future patients.
Allow other researchers to access the data in order to reproduce the results of a published trial, synthesize results across trials, and carry out additional or exploratory analyses. Such secondary uses of the data will increase the benefits to society and future patients in terms of knowledge gained from the clinical trial and the contributions of the trial participants.
Policies regarding responsible sharing of specific clinical trial data at particular times in the life cycle of a clinical trial need to balance these countervailing goals and interests. To strike a reasonable balance, the committee proposes releasing specific types of clinical trial data “packages” at different timepoints in the life of a clinical trial
Interesting comments, may I add why put out a PR for USFDA on a major holiday in the US? Well definitely moving forward with Trials and creating new cases seems to be a given, so plenty of patients and a strong need for treatments remains.
"Remembering all those that didnt make it back, Physically or mentally". Also all the "collateral damage" of Lives and society. May The Efforts made be Rewarded with proportional successes...GLTA...
Thanks guys, the same sources I found. Looks to me like no selling by officers or Directors or 3-10%+ owners. Just apparent accumulation of grants, warrants and even buying (Chris 20k, others?).
I also have not seen the volume necessary to move (sell) the many millions of shares, JMHO.?.
I also have learned to trust AMG's opinions who weighed in too. Shell, your math seems plausible but I dont see the filings for insiders. PPs were sold to investors not insiders, IMO, but I dont see the needed volume for them selling. If investors attain 3%+ holdings they will need to file.(?)
I believe patience will pay off big here. ALI / IPF, CKD, NASH.
I did find that all trials done in SK have NDAs under CRIS/ICMJE rules until findings are publicly released.
OAN, I knew that too. Sometimes less is more...GLTA...
Question for the Canadian side. Here in USA a Form 4 is needed for any sale of stock or warrants or beneficially owned shares for Directors, officers, or 5% owners. So how does Canada handle this, there are claims of huge flipping by some Directors at the least. Am I missing the Cdn filings?
On another subject, The long term Kidney damage from COVID ( and medications) is reported in at least 1/3 of recovered patients. AGN does CKD and a drug was planned for repurposing trials. Dr Moroue touched on this recently when discussing the recent PP...
The discussion of moving forward with other Drugs reminded me of this post. 36% suffering Kidney issues.
Well AGN (NASH?) has been / is researching CKD specific Drugs and also NASH / IBD drugs. There appears to be a increased demand for treatments developing so maybe our guys have identified something, maybe like the NDMA response being tested in Ifenprodil. Maybe even applying for Rights to specific uses as they did with Ifenprodil with some of the raised Ca$h. Maybe pushing Forward with Trials of other Drugs, seems logical...GLTA...
Nice find, walk22...
https://news.google.com/articles/CBMid2h0dHBzOi8vdGhlaGlsbC5jb20vcG9saWN5L2hlYWx0aGNhcmUvNDk3NzE1LWtpZG5leS1kYW1hZ2Utc2Vlbi1pbi1vbmUtdGhpcmQtb2YtY292aWQtMTktcGF0aWVudHMtc3R1ZGllZC1pbi1uZXctcmVwb3J00gF7aHR0cHM6Ly90aGVoaWxsLmNvbS9wb2xpY3kvaGVhbHRoY2FyZS80OTc3MTUta2lkbmV5LWRhbWFnZS1zZWVuLWluLW9uZS10aGlyZC1vZi1jb3ZpZC0xOS1wYXRpZW50cy1zdHVkaWVkLWluLW5ldy1yZXBvcnQ_YW1w?hl=en-US&gl=US&ceid=US%3Aen
Having NASH contribute something to AGN would be nice...JMH(misguided)O...
Setting up the Multinational 2b/3 Clinical Trials with help thru CRO NOVOTECH. USFDA next, MULTINATIONAL, get it.?.
In addition to Australia, the Company is also planning to conduct the multinational phase 2b/3 clinical study in Canada and the U.S. Algernon has already received clearance for the clinical study in Canada and is preparing to file an investigational new drug (IND) application with the U.S. FDA.
“Thanks to the hard work of our CRO partner Novotech, this ethics submission is yet another important step in the Company’s COVID-19 clinical development program,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals Inc. “The Algernon team is working hard to finalize the U.S. FDA IND application and will be updating the market on its progress shortly.”
Great points, 36% suffering these issues after current treatments!
Yes it sure seems like they have, just check out the Intro above or their web site.
NASH / Chronic Kidney Disease and IBD are targeted repurposed drug efforts. Maybe they have already thought of this when the recent PP cash raise was done. Some comments in recent news releases seem to imply other drug testing besides Ifenprodil...GLTA...
Give it a break, HOW can Anyone trade 10sM shares on this volume.?. They are selling a few MAYBE but roughly 50% of outstanding, really? What is killing the PPs is the 1k to 10k $.02 flippers...JMHFO...GLTA...
Yes, proper Banking may have useful, for sure. I just found this, it explains some...OLd but.
https://businessden.com/2020/04/22/golden-based-cannabis-company-files-for-chapter-11-bankruptcy-on-4-20/
Yea, lots of Cert of Services (lawyer bills) same as with '911' case. Still nothing on Court Listener where we can see it without subscription.
Fkn 4/20/2020. KMA.
$5M debt with min $13M revs. Lawyer's fees and "management" stupidity and greed...
As I questioned before, what is the guesses on the float for us all to deal with. Warrants ( most restricted ) when traded after purchase by a "major 5%+ holder" needs a SEC filing, right?. Chris/NASH/etc obviously are major holders and we ass-u-me Kal too. So 109M minus 40% is us and 57m options/warrants possibly allowed to trade, plus the recent PP and costs, all held by majors now allowed in August? How do they flip without filing?.
Doesn't this put a different wrinkle on everything? Is Canada different?
Too confusing for an old Crpl that had interest in FAIMS/Breathalyzer stuff which died here (bth+blo) then I was stuck, then gifted thru repurposing as the Pandemic causes ALI.
BTW, the Trials newly posted for 2b/3 COVID (NCT04382924) which is assumed Canada but was stated as "international Trials" is obviously different than the USFDA IPF/Cough (NCT04318704). 2b/3 is set up for 642 patients with COVID related lung Damage.
Also IMO, when S Korea says they will do something, others can depend on ROK to follow thru...GLTA...
Can not find on Court Listener but Pace has all this. I depend on CL so someone with access needs to open it all...
https://www.pacermonitor.com/public/case/33642494/United_Cannabis_Corporation
Opening clubs in Souel and I guess other places has led to many new COVID cases. I noticed that the S Korean's affected are mostly younger as compared to the US with mostly older or those with immune issues. Different strain maybe.?...GLTA...
https://en.yna.co.kr/view/AEN20200511001600315?section=science/medicine
Yes, Sad the flippers and Kal team cant control themselves and let a great thing go run before snatching every possible greed. Although I do believe taking some profits is deserved and smart, especially with what some investors have endured. I hope the sister spends the Raise intelligently.
This and other Breathalyzer Ideas are trashed now for sure with issues of Masks etc everywhere. (FAIMS too?/imsc/blo/bth)... Truth.
Hope most are holding at sister what they feel comfortable with and certainly enough for the possible future successes. You were deeper invested than most at both so I respect any moves made. Also respect your long time efforts to disseminate proper info and personal opinions even when they headed in a different direction than my opinions or may have infringed with others. Respect the Flags of all and their efforts. The public and private Banter was fun. Looking for more, LOL...
Good Luck to You Sir.
IMO, the patent court costs are the BK reasons and the path of CNAB was tinctures and THC related. CBD oils from Hemp were the new focus and they now hope to Reorg thru BK if allowed. Jamaica / CRD, Magnolia in SC, Tennessee, Mead Colorado etc and the proprietary extraction method are all CBD. Maybe they can pull this out/off and we wont be on the Ben Dover plan...GLTA...
SEOUL, May 8 (Yonhap) -- South Korea is conducting clinical tests for seven existing drugs to see if any of them can effectively treat the new coronavirus, a government official said Friday, noting a positive outcome of the tests may lead to the development of a cure for the virus before the year's end at the earliest.
"We expect, not all seven, but some of them may be launched later this year at the earliest," the official said in a Seoul meeting to review government support for efforts to develop drugs and vaccines for the potentially deadly virus.
Well Ifenprodil is Launching Today, May 8, so it looks to me like we are one of the First to go to Clinical Trials...GLTA...
Enrolment is discussed in the 4/23 video @ 4:30 to 5;30 minutes. Dr Moroue said patients are already under Dr Dong's care and signing permissions were in process. Seemed to imply (to me) things were compressed time frame for start...GLTA...
https://ca.proactiveinvestors.com/companies/news/918009/algernon-pharmaceuticals-receives-ok-from-south-korea-for-phase-two-study-of-ifenprodil-918009.html
Most expected some capital raise for preparation of the FOUR Trials. This stuff doesn't get done for Free and waiting for Grants/etc, maybe, GLWT. But paying CASH ALWAYS gets things done much better than waiting with a hand open wondering what will fill it first, wishes or BS.
IFENPRODIL is a possibly GOLD Ticket on the Blast-off Train... There's my one time one liner Pump. Please desist with the excessive one liners pumps with no actual info or discussions... JMHFO...GLTA...
I 'think' they needed to plan for the USFDA and Australia Trials at the least and possibly Canada too. Grants/Free money, IDK/maybe. But...
Dont know what the actual control is but 40% to NASH/AGN, (etc), then the PPs, great for new investors but tough on longest.
Sure this took some shine off and showed realities of either success in S.K., announcements for other Trials and moving strong past $2 or ?/?...
I also 'think' they knew this would be a last chance but they probably pretty much KNOW which way the wind will blow. Four Actual Phase 2+ TRIALS. UP!
...JMFSOs...GLTA...
Why SK was successful in their fight of COVID-19, travel restrictions / distancing / tracking / testing thru their single payer health system / early and coordinated with continued efforts. Epicenter was Teagu, way south near Pusan.
"The South Korean government has devoted over $100 million to buy medical supplies and build isolation rooms as the fight against COVID-19 is expected to stretch into the coming months."
https://www.businessinsider.com/coronavirus-south-korea-tech-contact-tracing-testing-fight-covid-19-2020-5#the-government-is-also-stockpiling-infrared-cameras-to-detect-fevers-along-with-other-medical-equipment-4
Yonhap news shows 10,793 total Korean Covid patients with 9,183 released/recovered. 1610 still hospitalized.
The Dong A University hospital also has " medical Tourism " which seems to imply foreigners are being treated there besides Korean citizens.
Seems to me to be a sufficient pool of patients to get the initial 40 needed for the Ifenprodil Trial...
Ifenprodil is in process of starting FOUR Trials. At Phase 2, 2b and possibly quickly progressing to Phase 3 in Canada. Yea we had to raise CASH to do it, Right. At least we will see several sources of Data that we hope will allow full review and confirmation of results.
At least Remdesivir is cheap, @ about $10 an infusion / vial.(?)
Cerocal @ about $35/10 pills. (?) (maybe as a cocktail?)
Millions of current and possible future long term needs.
Hospitalizations costs $10k++/day.
Compared to Cancer drugs per infusion, Ipillimaud $80k, Katruda $12k, Optivo $7k. (no ?,got bills)
BTW, check out Remdesivir/Giliad relationships with Wuhan Virologic Institute. How do they explain this. Accidental release?
Trump's pump of questionable drugs endangers all and Dr. Fauci touting a questionable/changed benefit with limited available data erodes his credibility? I respect the need for positive encouragement, BUT...GLTA...
There it is! Four phsae2 trials and Cash to make them go...
The Korean Phase 2 trials appear to me to be more directed toward COVID-19 thru MOHW, South Korea. Ifenprodil is an approved drug in South Korea for other indications and is being tested for Repurposing, IMO. They have a specific Korean Lead investigator/sponsor/University led with Dr. Dong.
" The Phase 2 human trials will consist of 40 patients during a 4-week trial and will be testing the efficacy of Ifenprodil in infected patients with Covid-19. Dr. Dong Sik Jung, Professor in the Division of Infectious Disease of Dong-A University Hospital in Busan, South Korea will be the lead principal investigator overseeing the trials and patient enrollment for Phase 2 clinical trials is set to take place on May 8th, 2020. The CEO of AGN Christopher Moreau stated, “This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program”.
Watch 4/23 Video, mins 4:00 to 5:30 for Recruitment, Dr Moroue explains that the patients are ready and about Dr Dong... heck watch it all again...
Looks to me like the current USFDA authorized trials are set more specifically for "Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough", NCT04318704. The Exclusion Criteria section has lots of limits and the Inclusion Criteria section does not mention COVID and appears to me to be IPF specific.
Novotech efforts for Ifenprodil in Austrailia also seem to be directed at IPF and ALI, IMO.
Now Canada Trial approvals seem eminent,, with their Phase 2b/3 plans. Canada seems to present the best of all possibilities for Algernon Investors.
That's FOUR Trials !! The South Korean effort starts May 8...
As you say They Have Money in the Bank...
Call me a sore thumb.
Maybe check out Giliad/Remisifir(?) relationship with Wuhan, VI.
AGN now has two separate agencies on opposite sides of the world apparently seriously accepting the theories for the science behind NP-120 and will put it into Trials. The other two Trials sites are in process of accepting. This shows me the broad spectrum of support data developed for NP-120. Fantastic Job by our management team!!!
IFFF/WHENNN
Lots of talk of selling either the drug or the whole company. But I also hear the Licensing/Partnership path discussed. IMO this is the Golden ticket and with legal support I believe it can be done. So many separate markets / the Whole World where a License/Partnership process would allow Many drug manufactures to make Ifenprodil. This would distribute our drug the fastest and to the widest coverage... World Wide. Sure I'd love a $B buyout but just think of a Licensing/Partnership format.
Would NOVOTECH be a possible representative to run Licensing deals? I'm sure there are companies that can handle the job that would represent our interests and be thrilled to be middlemen.
At the very least it is a bargaining chip. At least that is what my Hornitos said...HMMMM...
Sure glad I have been buying more lately, looks like a JUMP in the AM and then for quite awhile...GLTA...
Great stimulus for the stock. I believe it is up to Longs to start the move here. "Buying the dips with lowball bids and small change ? OK, but NOW is the time to help IF You're a Believer...JMHFO...
Looks to me like the current USFDA trials are set more specifically for "Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough", NCT04318704. The Exclusion Criteria section has lots of limits and the Inclusion Criteria section does not mention COVID and appears to me to be IPF specific. Novotech efforts for Ifenprodil in Austrailia also seem to be directed at IPF and ALI, IMO.
The Korean Phase 2 trials appear to me to be more directed toward COVID-19 thru MOHW, South Korea. Ifenprodil is an approved drug in South Korea for other indications and is being tested for Repurposing, IMO. They have a specific Korean Lead investigator/sponsor/University led with Dr. Dong.
" The Phase 2 human trials will consist of 40 patients during a 4-week trial and will be testing the efficacy of Ifenprodil in infected patients with Covid-19. Dr. Dong Sik Jung, Professor in the Division of Infectious Disease of Dong-A University Hospital in Busan, South Korea will be the lead principal investigator overseeing the trials and patient enrollment for Phase 2 clinical trials is set to take place on May 8th, 2020. The CEO of AGN Christopher Moreau stated, “This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program”.
!! Watch 4/23Video mins 4:00 to 5:30 for Recruitment, heck watch it all again...!!
I hope that the Canada Trial approvals, with their Phase 2b/3 plans, work out and then move QUICKLY. Canada seems to present the best of all possibilities for Algernon Investors.
The Algernon management team's use of our CRO and their many cunsultant's help, also as discussed in the 4/23 Video, shows the many paths they are developing now just for NP-120. Several layers of confirmations and data from around the World!.
My respect for the efforts and building acheivements of our team. Yes, "this has a different feel"..GLTA...
Great posts and several well researched stickies to read explaining current progress and the science behind Ifenprodil. Then take some time to visit the Algernon web site and watch some recent NP-120 Videos and even learn about other repurposed Drug initiatives in the pipeline.
This company appears to me to have a world class solution and support from Govs in Canada, South Korea and the US FDA in the current Fight of COVID. I'm certainly not going to flip for pennies here when the sky is our only limit.
We are so lucky to be part of "a small handful of companies" that have Real contributions to Mankind's fight for relief and treatments during the COVID Pandemic and recovery.
Thanks to the early posters and Congratulations to the Long time longs here and to the early crowd that has found this wonderful possibility for the treatment of the ( Fatal ) Lung /cough symptoms of COVID. And so much more... Good Luck To All...
I wonder about the style of Ifenprodil that will be used in the SK trials. Will it be some kind of a pill or the new formulated intravenous method? Either way looks like AGN has a plan and something stashed away to use...GLTA...
Algernon Pharmaceuticals Inc. and subsidiary Nash Pharmaceuticals Set aside drug supply of NMDA antagonist for compassionate use from phase II study for idiopathic fibrosis and chronic cough based on an independent study that showed a 40% improvement in mortality and significantly reduced acute lung injury (ALI) in an independent H5N1 animal study; originally developed as Cerocal by Sanofi SA to treat circulatory disorders in the French and Japanese markets; company is beginning production with a new injectable and long-acting oral release formulation, in order to be prepared for new U.S. clinical trials for COVID-19 and ALI. Algernon announced that CRO Novotech had identified physicians in South Korea who have agreed to conduct a phase II trial of ifenprodil for coronavirus patients; as of April 2, protocol finalized for physician-initiated study in South Korea with submission for approval ."
and of course the Trials start by May 8 th at the latest, so recruitments of patients are under way right now possibly. Also of course there must be some of the drugs available...GLTA...